Company News

 

Tauriga Sciences Inc. to Form Wholly Owned Subsidiary Focused on the Development …  View


Tauriga Sciences, Inc. announced that it has secured additional capital..  View


2014 – 2015 Financials Reported – Company On Track To Regain Reporting Status. View

LATEST TAURIGA SCIENCES UPDATES

TAURIGA SCIENCES INC. DISCLOSES ADDITIONAL PERSONAL INVESTMENT OF $55,000 USD FROM ITS CHIEF EXECUTIVE OFFICER SETH M. SHAW; INVESTMENT STRUCTURED AS EQUITY PRIVATE PLACEMENT PRICED AT $0.00125

NEW YORK, NY, Jun 21, 2017 (Marketwired via COMTEX) — NEW YORK, NY–(Marketwired – Jun 21, 2017) – Tauriga Sciences Inc. (otc pink:TAUG) (“Tauriga” or “the Company”), a company engaged in the building of life sciences businesses and technologies, has today announced that is Chief…

Read More

Tauriga Sciences, Inc. Reiterates That it Has No Plans to Enact Any Type of Reverse Split for the Foreseeable Future

NEW YORK, NY–(Marketwired – Jun 19, 2017) – Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or “the Company”), a Company engaged in the building of businesses in the life sciences space, has today confirmed to shareholders that it has no plans to enact any type of Reverse Split for the foreseeable future. …

Read More

TAURIGA SCIENCES INC. INCORPORATES ITS NEW AND IMPROVED LABEL DESIGN FOR THE UPCOMING LAUNCH OF ITS CUPUACU BUTTER LIP BALM PRODUCT

NEW YORK, NY–(Marketwired – Jun 16, 2017) – Tauriga Sciences Inc. (OTC PINK: TAUG) (“Tauriga” or “the Company”), a Company engaged in the building of businesses in the life sciences space, has today announced the completion of…

Read More

Fully committed to commercializing innovation to enhance personal wellness, improve our environment and create lasting shareholder value.

Balanced Innovation and Commercialization

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and on developing a proprietary synthetic biology platform technology through its wholly-owned Pilus Energy subsidiary.

The Company’s business model is to create an attractive and balanced portfolio of life sciences assets without typical clinical regulatory timelines.

Tauriga’s main focus for the last year has been getting audited financials and relisted on BB. Due to what we believe was gross malpractice by our auditors, TAUG was delisted from the BB. But we are always looking for exciting opportunities to increase shareholder value.
Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), a diversified life sciences technology Company, today announced that it has completed an equity private placement for $105,500 USD to date comprised of accredited individual investors as well as one institutional investor.
Recently the Company added Frank Orlowski, Sr. Director at Pfizer (PFE); and Keith Berman  CEO of Digital Diagnostics Inc (DECN). The Company remains committed to finding the right opportunity to joint venture or merge with.